NVAX
Novavax Inc
Price:  
8.08 
USD
Volume:  
4,433,274.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

Novavax WACC - Weighted Average Cost of Capital

The WACC of Novavax Inc (NVAX) is 7.4%.

The Cost of Equity of Novavax Inc (NVAX) is 7.90%.
The Cost of Debt of Novavax Inc (NVAX) is 4.60%.

Range Selected
Cost of equity 6.70% - 9.10% 7.90%
Tax rate 0.50% - 1.10% 0.80%
Cost of debt 4.50% - 4.70% 4.60%
WACC 6.3% - 8.5% 7.4%
WACC

Novavax WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.61 0.76
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.70% 9.10%
Tax rate 0.50% 1.10%
Debt/Equity ratio 0.18 0.18
Cost of debt 4.50% 4.70%
After-tax WACC 6.3% 8.5%
Selected WACC 7.4%

Novavax's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for Novavax:

cost_of_equity (7.90%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.61) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.